Intellia to present four-year lonvo-z data in hereditary angioedema at ACAAI 2026
NTLA•Intellia Therapeutics plans to present seven studies of lonvoguran ziclumeran in hereditary angioedema at ACAAI’s November 12-16, 2026, meeting, including four-year data on durability and safety.
1. Planned presentations
Intellia Therapeutics said the studies will report consistent benefit across Phase 3 HAELO patient subgroups and improved quality of life after one-time treatment. Oral presentations on November 14 will cover four-year durability and safety, freedom from attacks, and long-term preventive treatment. An investor webcast on November 12 will review clinical data and preparations for a planned commercial launch.
